The HCPCS/CPT code(s) may be subject to Correct Coding Initiative (CCI) edits. This policy does not take precedence over CCI edits. Please refer to the CCI for correct coding guidelines and specific applicable code combinations prior to billing UnitedHealthcare. It is not enough to link the procedure code to a correct, payable ICD-9-CM diagnosis code. The diagnosis must be present for the procedure to be paid. Compliance with the provisions in this policy is subject to monitoring by pre-payment review and/or post-payment data analysis and subsequent medical review. The effective date of changes/additions/deletions to this policy is the committee meeting date unless otherwise indicated. CPT codes and descriptions are copyright 2010 American Medical Association (or such other date of publication of CPT). All rights reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS restrictions apply to Government use. Fee schedules, relative value units, conversion factors, and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Current Dental Terminology (CDT), including procedure codes, nomenclature, descriptors, and other data contained therein, is copyright by the American Dental Association, 2002 Association, , 2004 . All rights reserved. CDT is a registered trademark of the American Dental Association. Applicable FARS/DFARS apply. Summary Overview Capsule endoscopy is a wireless noninvasive diagnostic imaging device for use in viewing the gastrointestinal tract, especially the small bowel, which is not accessible to standard upper endoscopy and colonoscopy. A small capsule (approximately 11x30mm) is swallowed and moves through the GI tract propelled by peristalsis, transmitting video pictures. The video images are transmitted to sensors taped to the body and stored on a portable recorder. The strength of the signal is used to calculate the position of the capsule as it passes through the GI tract. Video images are stored on a portable recorder and later downloaded to a computer, from which they may be viewed and documented. The capsule passes naturally from the body with the stool, and since it is disposable, is not recovered.
Coverage Indications

I. Occult gastrointestinal bleeding
This test is indicated for the diagnosis of occult gastrointestinal bleeding in the anemic patient when: 1. The site of bleeding has not previously been identified by upper gastrointestinal endoscopy, colonoscopy, push endoscopy or other radiologic procedure, and EGD endoscopy and colonoscopy have been performed during the same episode of illness. 2. The diagnosis of angiodysplasias of the GI tract is suspected, and EGD endoscopy and colonoscopy have been performed during the same episode of illness. 3. Patients have documented continuing GI blood loss and anemia secondary to bleeding, and EGD endoscopy and colonoscopy have been performed during the same episode of illness. II. Other indications:
1. When the diagnosis of Crohn's disease is suspected but not diagnosed. 2. When the diagnosis of Crohn's disease is known but it is necessary to determine whether there is involvement of the small bowel as well. 3. When a diagnosis of colitis of an indeterminate type, affecting the colon, is known and a more specific diagnosis is sought by evaluating possible small bowel involvement. 4. As a primary procedure in the evaluation of suspected, but undiagnosed, small bowel neoplasm, regional enteritis, or malabsorption syndrome. 5. Esophageal capsule endoscopy may be used in the evaluation of esophageal varices in patients with portal hypertension, as an alternative to upper GI endoscopy.
Reimbursement Guidelines
Capsule Endoscopy is payable when all of the following criteria are met:
• Patients are receiving services using FDA approved devices.
• The service is performed by physicians trained in endoscopy or in an independent diagnostic testing facility under the general supervision of a physician trained in endoscopy procedures. Limitations When done for gastrointestinal blood loss: There are insufficient studies available to support coverage.
• Capsule endoscopy of the esophagus has been used by some practitioners for patients with suspected gastroesophageal reflux disease, Barrett's Esophagus, or esophageal varices. However, mere visualization will not diagnose Barrett's Esophagus (i.e., a biopsy is needed), and there is no need, nor is it standard, to monitor treatment of GERD, varices, etc. by this method (i.e., patients with symptoms will need upper endoscopy to determine severity of disease and potential complications). Since the findings will not alter the treatment plan, these will be denied as not medically necessary. Contraindications Contraindications include: pregnancy, cardiac pacemaker and other implanted electro-medical devices, swallowing disorders, known or suspected GI obstruction, strictures or fistulas based on the clinical picture or preprocedure testing. The capsule is not FDA approved for use in children.
Coverage Indications Wireless Gastrointestinal Motility Monitoring Systems (CPT code 91112)
A Wireless Gastrointestinal Motility Monitoring System is an ingestible capsule (WMC) with a trade name SmartPill. The SmartPill records data enabling the estimation of regional and total gastrointestinal motility. The device has FDA approval to evaluate patients with suspected delayed gastric emptying and the evaluation of colonic transit time in patients with chronic idiopathic constipation. The capsule device measures pH, temperature, and pressure while traveling through the GI tract -sending the data to a wireless receiver worn on or near the patient. The data can be used to determine GI motility, gastric emptying, small bowel transit, colonic transit, and whole gut transit times. The capsule can also provide pressure patterns within the GI tract. The study can be done in a physician office after the patient has discontinued use of all medications that affect the GI tract.
Reimbursement Guidelines
The Wireless Mobility Capsule has been studied in many centers, does not use radioactive materials, and has minimal safety risks. UHC will cover the device when:
• It is used by a gastroenterologist trained to use and interpret the results.
• It is used to evaluate and/or treat patients with suspected gastroparesis of any nature.
• It is used to evaluate colonic transit in patient with chronic idiopathic constipation lasting over 6 months.
• Basic clinical investigations, including endoscopy, have failed to elucidate a diagnosis.
Limitations
The WMC should not be administered to patients with a history of gastric bezoar, swallowing disorders, dysphagia, suspected strictures/ fistulae in the GI tract, physiologic gastrointestinal obstruction, GI surgery within the previous 3 months, Crohn's disease, diverticulitis, or an implanted or portal electromechanical medical device (such as pacemaker or infusion pump 
